NEWS OF THE WEEK: Gene Hackman final autopsy released
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030
"Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the complex pathology of the disease." BOSTON, Aug. 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Disease-Modifying Therapies for Alzheimer's Disease: Global Markets" is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030. The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa). This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities. The factors driving the market's growth include: High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies. Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development. Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $235.8 million Market size forecast $13.1 billion Growth rate CAGR of 67.8% for the forecast period of 2025-2030 Segments covered Target Type, Drug Type, Drug Molecule Type, and Region Regions covered North America, Europe, Asia-Pacific, South America, Middle East and Africa Market drivers • High unmet need in AD treatment. • Use of biomarkers to accelerate AD DMTs approval. Interesting facts: As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules ( There are very few DMTs targeting the moderate to advanced stages of AD. Emerging startups: AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits. TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD. The report addresses the following questions: What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?- The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period. Which market segments are covered in the report?- Target type, drug, molecule type, and region. Which target type will be dominant through 2030?- By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030. Which molecule type market is growing the fastest?- The large molecule segment is the fastest growing market. What are the key challenges in of the market?- Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs. Market leaders include: ALZHEON INC. ANAVEX LIFE SCIENCES CORP. ANNOVIS BIO INC. BIOGEN BIOVIE INC. EISAI CO. LTD. JOHNSON & JOHNSON LILLY NOVO NORDISK A/S TAURX PHARMACEUTICALS LTD. Related reports: Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential. Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC
Fox News
a day ago
- Fox News
Melanoma can be deadly: What to know about the disease that killed Kelly Clarkson's ex
Days after Kelly Clarkson's ex-husband, Brandon Blackstock, passed away at the age of 48, the cause of his death was revealed. On August 11, it was reported that the talent manager died after a private battle with melanoma, a form of skin cancer. "Brandon Blackstock passed away peacefully at his home in Butte, Montana on August 7 under hospice care surrounded by his family," Silver Bow County Coroner Dan Hollis told Fox News Digital. "It is with great sadness that we share the news that Brandon Blackstock has passed away. Brandon bravely battled cancer for more than three years. He passed away peacefully and was surrounded by family. We thank you for your thoughts and prayers and ask everyone to respect the family's privacy during this very difficult time." The singer, who was married to Blackstock for seven years before their divorce in 2022, reportedly "remained protective" of her ex as he battled cancer for three years. Skin cancer is the most common type of cancer in the U.S. — with one in five Americans developing the disease by the age of 70. Melanoma is the deadliest form of skin cancer, expected to take the lives of more than 8,400 people in the U.S. this year, according to the American Cancer Society. "Melanoma has a significantly higher chance of spreading than basal cell and squamous cell carcinomas, the most common types of skin cancer," said Marcus Monroe, MD, surgeon and investigator with the Huntsman Cancer Institute and associate professor at the University of Utah School of Medicine, previously told Fox News Digital. The chances of melanoma spreading to other locations increases with each stage of cancer. "For the earliest stage, this risk is estimated at less than 5%, increasing for patients with stage 2 disease to a wider range, from 5% at the low end up to 40% to 50% for the most advanced stage 2 patients," said Monroe. In stage 3 patients (those with regional spread either via in-transit metastases or to adjacent lymph nodes), up to 30% to 40% will develop distant metastases, with a 16% to 17% risk of brain metastases, the doctor added. Melanoma is the deadliest form of skin cancer, expected to take the lives of more than 8,400 people in the U.S. this year. The brain and lungs are the most common sites of metastasis for melanoma, experts confirmed. If the patient has lesions that are deep in the skin or involve the lymph nodes, the chance of melanoma spreading is higher — anywhere from 20% to 70%, according to Jose Lutzky, MD, director of cutaneous oncology services at the Sylvester Comprehensive Cancer Center in South Florida. Metastatic melanoma was once considered mostly treatment-resistant because it did not respond to traditional chemotherapy and radiation, noted Dr. Joshua Strauss from Advanced Care Oncology and Hematology Associates of the Atlantic Medical Group in Morristown, New Jersey. "Nowadays, using targeted therapies and immunotherapy survival has been dramatically improved, and there is a possibility of long-term remission with treatment," Strauss previously told Fox News Digital. Lutzky noted that melanoma is almost always curable by surgical removal when it's detected early. "Because of advances in the treatment of melanoma over the last 10 to 15 years, even very advanced melanoma can be cured in up to 50% of cases with modern immunotherapy treatment," he told Fox News Digital. "More recently, cell therapy has been approved to treat those advanced melanomas that do not respond to immunotherapy." To prevent melanoma, it's important to reduce exposure to ultraviolet radiation, especially in people with lightly pigmented skin, Strauss advised. "Sunscreen and sun-protective clothing are critical," he said. The American Academy of Dermatology recommends applying water-resistant sunscreen with broad-spectrum protection against UVA and UVB rays, and SPF 30 or higher, before sun exposure. "Indoor tanning bed use should be avoided because it is known to be associated with increased melanoma risk," Strauss added. High-risk individuals should also have yearly skin checks with a dermatologist. "This includes individuals with a personal history of skin cancer, family history of melanoma, people who take medications that suppress the immune system, and people who are highly sun-sensitive, such as those with red or blond hair, light skin pigmentation, significant freckling and light eye color," the oncologist said. For more Health articles, visit Strauss uses the acronym ABCDE to differentiate between a normal mole and a melanoma. "Moles with Asymmetry, irregular Borders, multiple Colors, Diameter larger than a pencil eraser, and Evolving or changing characteristics require further evaluation," he said. Fox News' Christina Dugan Ramirez contributed reporting.
Fox News
a day ago
- Fox News
Cracker Barrel customers revolt against remodels, plus workers unearth 1,000-year-old tombs
'WHAT GUESTS ASKED FOR': Cracker Barrel responds to customer complaints about restaurant renovations. URBAN SECRETS: Workers found two pre-Incan tombs during gas line construction, including one holding a 1,000-year-old skeleton. NO-BRAINER: Neurologists identify common foods that can contain dangerous neurotoxins and tapeworms that could harm brain health. STRANGE BUYS – From a tortilla blanket to an ostrich pillow, dive into Amazon's extensive collection of weird and wonderful products. Continue reading… CALLING ALL CROSSWORD PUZZLE LOVERS! – Play our Fox News daily crossword puzzle for free here! And not just one — check out the multiple offerings. See the puzzles... Fox News FirstFox News Opinion
